Oragenics, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014; comparisons are with 2013. The filing also reports fourth-quarter results. Oragenics is a development-stage biotechnology company pursuing lantibiotic antibiotics and live biotherapeutic products (LBPs), alongside commercial oral probiotics sold under the ProBiora3 and Evora brands.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net revenue | $939,926 | $1,032,233 |
| Gross profit | $570,329 | $688,879 |
| Research and development | $3,065,053 | $9,358,957 |
| Selling, general and administrative | $3,321,771 | $7,540,152 |
| Operating loss | $(5,816,495) | $(16,210,230) |
| Net loss | $(5,789,519) | $(16,068,754) |
| Basic and diluted loss per share | $(0.16) | $(0.56) |
| Cash used in operating activities | $(5,559,130) | $(6,764,533) |
- Revenue fell about 9%; management attributes the change principally to lower grant revenue and sales-return allowance effects. ProBiora3 product sales were reported as $939,926 in 2014 versus $949,593 in 2013; the filing’s revenue descriptions do not clearly reconcile product sales, grants and total revenue.
- Management reports gross margins of 69.9% for 2014 and 71.0% for 2013. These percentages do not match gross profit divided by the reported total revenue figures; the filing does not clearly explain the difference in calculation basis.
- Year-end cash and cash equivalents were $10.45 million, down from $16.28 million. Working capital surplus was $10.23 million, versus $15.81 million. Total assets were $11.13 million and shareholders’ equity was $10.34 million.
- Current liabilities were $796,272, including $64,840 of short-term notes payable. The company reported no material long-term debt; notes primarily financed insurance premiums.
- Management said available cash was expected to fund operations through March 2016, but additional financing would be needed thereafter to sustain operations and pursue development. No committed financing sources were identified.
Material changes and business developments
- Net loss narrowed substantially, primarily because 2013 included a $6.0 million noncash Intrexon technology-access fee for the LBPs collaboration, as well as higher stock-based compensation and other expenses. This improvement does not represent profitability: operating losses and negative operating cash flow continued.
- R&D expense declined 67% and SG&A declined 56% year over year. The company also sharply reduced probiotic advertising, with advertising and marketing expense of $61,085 in 2014 versus $895,078 in 2013.
- In December 2014, Oragenics announced it would explore strategic alternatives for its probiotic business, potentially including a partnership, joint venture or sale. No transaction was assured.
- CEO John Bonfiglio resigned in October 2014. CFO Michael Sullivan served as interim principal executive officer while a successor was sought.
- Common shares outstanding increased to 36,178,944 at year-end from 35,993,944 a year earlier. The filing also lists 2,532,094 warrants and 820,865 options outstanding, creating potential dilution.
Outlook, risks and unusual items
- Antibiotics: MU1140 and related lantibiotic candidates remained in nonclinical development. Management anticipated an FDA pre-IND meeting in the second half of 2015 and a potential IND filing in 2016, dependent on manufacturing and nonclinical progress. No candidate had entered human trials under this program.
- LBPs: Management was reconsidering the initial oral-disease indications and evaluating alternatives believed to offer better commercial potential. These programs remained early-stage.
- Probiotics: Sales and marketing had produced limited growth, and strategic alternatives were under review. The company also disclosed that a supplier planned to stop producing two of the three bacterial strains used in ProBiora3; replacement supply and production contracts were important execution issues.
- Funding and profitability: Oragenics had accumulated losses of approximately $75.9 million, recurring operating losses and negative cash flow. Management expected substantial future losses and warned that financing might be unavailable or dilutive, potentially forcing delays or cuts to development programs.
- Collaboration obligations: Intrexon receives 25% of gross profits from lantibiotic products and 50% of sublicense revenue under that program; the LBPs agreement provides for a 10% net-sales payment and milestone payments of up to $17 million. No milestones under either agreement had been achieved by year-end.
- Other risks and contingencies: Drug candidates face substantial regulatory, clinical, manufacturing and commercialization uncertainty. SMaRT Replacement Therapy development was discontinued after enrollment difficulties; a clinical hold remained for the non-attenuated strain. The SMaRT patent was scheduled to expire in June 2015. The company also disclosed ownership-change limits on tax-loss carryforwards.
- Controls: Management judged disclosure controls effective, but concluded internal control over financial reporting was ineffective because of a material weakness in segregation of duties. The independent auditor issued an unqualified opinion on the financial statements, but did not opine on control effectiveness.
- The filing reports no material legal proceedings and no share repurchases during the fourth quarter. No dividends were declared or anticipated in the foreseeable future.
Most important facts for investors to verify
- Cash runway assumptions, expected burn rate, and the timing, amount and terms of any required financing.
- The basis for the filing’s stated gross-margin percentages and reconciliation of product sales, grant revenue and total revenue.
- Progress on selecting a lead lantibiotic, contract manufacturing, nonclinical studies and the anticipated FDA milestones.
- Whether the probiotic business finds a buyer or partner and whether a reliable supplier is secured for all ProBiora3 strains.
- Plans to remediate the internal-control material weakness, and the potential dilution from outstanding warrants, options and collaboration milestones.